Gerresheimer AG · ISIN: DE000A0LD6E6 · EQS - Company News

FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*

Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU* Innovative combination product of furosemide and on-body device Ready-to-market device designed, developed and manufactured by Gerresheimer Patented device technology for precise administration  Düsseldorf, Germany, December 16, 2024. Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetics industries, announces that the US Food and Drug Administration (FDA) g...

XETR:GXI Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Gerresheimer AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (6)
Short Selling (DE) (37)
Short Selling (UK) (0)
16 December 2024 09:00AM
FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*
DE000A0LD6E6
Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU* Innovative combination product of furosemide and on-body device Ready-to-market device designed, developed and manufactured by Gerresheimer Patented device technology for precise administration  Düsseldorf, Germany, December 16, 2024. Gerresheimer, an innovative system a...
Gerresheimer AG
About the publication
11 December 2024 08:00AM
Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group
DE000A0LD6E6
Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group Complementary product portfolio and broad footprint of production sites in Europe Strengthening the market position as a full-service provider for the pharma and biotech industry Strategic reset of Moulded Glass business Düsseldo...
Gerresheimer AG
About the publication
02 December 2024 01:30PM
Gerresheimer builds new production capacities for glass syringes at Skopje site 
DE000A0LD6E6
Gerresheimer builds new production capacities for glass syringes at Skopje site  Expansion of the site in the Republic of North Macedonia with a new production hall for glass syringes Total investment volume of over EUR 100 million Around 250 new jobs for skilled workers from the region Ramp-up of syringe production starting by the end of 2024 ...
Gerresheimer AG
About the publication
14 October 2024 11:00AM
Solar power for Gerresheimer site in Momignies, Belgium
DE000A0LD6E6
Solar power for Gerresheimer site in Momignies, Belgium 2.3 MWp rooftop photovoltaic system on production building Gerresheimer increases share of green electricity in its energy supply Goal for 2030: 100% electricity from renewable sources Duesseldorf/Momignies, October 14, 2024. Gerresheimer, an innovative system and solution partner and a glo...
Gerresheimer AG
About the publication
30 September 2024 04:21PM
Adjustment of growth guidance for 2024 and 2025
DE000A0LD6E6
Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025  Düsseldorf, September 30, 2024 – Gerresheimer AG (ISIN: DE000A0LD6E6) is adjusting its growth guidance for 2024 and 2025 due to the significantly slower than expected market recovery 2024 and lower anticipated market growth in 2025 in the vial market. The guidance is also affected ...
Gerresheimer AG
About the publication
26 September 2024 12:30PM
Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU”
DE000A0LD6E6
Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU”  Market advances adoption of ready-to-use containers Improved operational efficiency in pharmaceutical manufacturing processes Increased patient safety with high-quality sterile primary packaging Düsseldorf, September 26, 2024. Gerresheimer AG (MDAX: G...
Gerresheimer AG
About the publication
16 September 2024 01:00PM
EcoVadis Gold with further improved score
DE000A0LD6E6
Gerresheimer: EcoVadis Gold with further improved score Gerresheimer among the top 3 % of all rated companies Overall result increased to 76/100 points Award underlines consistent implementation of the sustainability strategy Düsseldorf, September 16, 2024 - Gerresheimer, an innovative systems and solutions provider and global partner for the ph...
Gerresheimer AG
About the publication
16 September 2024 01:00PM
EcoVadis Gold with further improved score
DE000A0LD6E6
Gerresheimer: EcoVadis Gold with further improved score Gerresheimer among the top 3 % of all rated companies Overall result increased to 76/100 points Award underlines consistent implementation of the sustainability strategy Düsseldorf, September 16, 2024 - Gerresheimer, an innovative systems and solutions provider and global partner for the ph...
Gerresheimer AG
About the publication
11 July 2024 07:00AM
Gerresheimer remains on track in 1st half year 2024
DE000A0LD6E6
Gerresheimer remains on track in 1st half year 2024 Organic growth: revenues +1.7%, adjusted EBITDA +2.9% Plastics & Devices division with good revenue growth and significantly improved margin Guidance confirmed Düsseldorf (Germany), July 11, 2024. Gerresheimer, an innovative systems & solutions provider and global partner for the pharma...
Gerresheimer AG
About the publication
27 May 2024 01:00PM
Gerresheimer expands capacities for Medical Systems in the USA
DE000A0LD6E6
Gerresheimer expands capacities for Medical Systems in the USA Two-stage expansion of the Peachtree City, Georgia site Total investment volume of around USD 180 million More than 400 new jobs for skilled workers from the region Ramp-up of production beginning end of 2024 Düsseldorf / Peachtree City, USA, May 27, 2024 – Gerresheimer, an innovati...
Gerresheimer AG
About the publication
23 May 2024 07:00AM
Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business
DE000A0LD6E6
Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business Strategic acquisition: Complementary product portfolio and broad footprint with production sites in Europe Gerresheimer underpins leading market position as a full-service provider for the pharmaceutical and biote...
Gerresheimer AG
About the publication
23 May 2024 07:00AM
Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business
DE000A0LD6E6
Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business Strategic acquisition: Complementary product portfolio and broad footprint with production sites in Europe Gerresheimer underpins leading market position as a full-service provider for the pharmaceutical and biote...
Gerresheimer AG
About the publication
23 May 2024 06:16AM
Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group / Moulded Glass business to be strategically reviewed
DE000A0LD6E6
Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Moulded Glass business to be strategically reviewed   Düsseldorf, May 23, 2024. Gerresheimer Glas GmbH, an indirect subsidiary of Gerresheimer AG, has today signed a purchase agreement with funds advised by Triton ("Triton") for the acquisition of Blitz L...
Gerresheimer AG
About the publication
29 April 2024 01:00PM
Gerresheimer partners with RxCap to offer connected adherence solutions
DE000A0LD6E6
Gerresheimer partners with RxCap to offer connected adherence solutions  Gerresheimer subsidiary Centor receives exclusive distribution rights for pharmacies in the U.S. Adherence solutions enables pharmacies to offer remote therapeutic monitoring Digital therapy support leads to improved health outcomes Düsseldorf/Berlin, Ohio, USA, April 29, 2...
Gerresheimer AG
About the publication
29 April 2024 01:00PM
Gerresheimer partners with RxCap to offer connected adherence solutions
DE000A0LD6E6
Gerresheimer partners with RxCap to offer connected adherence solutions  Gerresheimer subsidiary Centor receives exclusive distribution rights for pharmacies in the U.S. Adherence solutions enables pharmacies to offer remote therapeutic monitoring Digital therapy support leads to improved health outcomes Düsseldorf/Berlin, Ohio, USA, April 29, 2...
Gerresheimer AG
About the publication
11 April 2024 07:00AM
Gerresheimer makes solid start to the financial year 2024
DE000A0LD6E6
Gerresheimer makes solid start to the financial year 2024 Organic growth: Revenues +2.8%, adjusted EBITDA +5.9%  Capacity expansion in the Americas, Europe and Asia progresses according to plan Guidance confirmed Düsseldorf, April 11, 2024 Gerresheimer, an innovative systems and solutions provider and a global partner for the pharma, biotech and...
Gerresheimer AG
About the publication
22 February 2024 07:00AM
Gerresheimer decisively continues on profitable growth course in financial year 2023
DE000A0LD6E6
Gerresheimer decisively continues on profitable growth course in financial year 2023 Organic revenue growth in 2023: +10.4% Organic adjusted EBITDA growth in 2023: +17.5% Favorable product mix boosts profitability High order backlog and global capacity expansion secure profitable growth for the years ahead   Düsseldorf, February 22, 2024. Gerr...
Gerresheimer AG
About the publication
04 January 2024 02:00PM
Gerresheimer and Aptar Digital Health collaborate to develop integrated solution for cancer therapy 
DE000A0LD6E6
Gerresheimer and Aptar Digital Health collaborate to develop integrated solution for cancer therapy  Subcutaneous administration of oncology drugs with digital therapy support Integrating Gx SensAir drug delivery device with Aptar's Digital Health platform Solution aims to improve the patient experience and quality of life of cancer patients   D...
Gerresheimer AG
About the publication
05 December 2023 10:00AM
Guido Pickert to head up Investor Relations at Gerresheimer
DE000A0LD6E6
Guido Pickert to head up Investor Relations at Gerresheimer Duesseldorf, December 5, 2023. Guido Pickert will join Gerresheimer AG, an innovative system and solution provider and a global partner for the pharma, biotech, and cosmetic industries, as Vice President Investor Relations with effect from January 2024. Pickert comes from Aixtron SE, wher...
Gerresheimer AG
About the publication
28 November 2023 10:25AM
Green electricity from wind for German production sites
DE000A0LD6E6
Gerresheimer: Green electricity from wind for German production sites Agreement signed with PNE AG to supply around 35 GWh per year CO2 emissions to be cut by around 18,000 t Gerresheimer increases share of green power in energy supply Goal for 2030: 100 % electricity from renewable sources Düsseldorf, Germany, November 28, 2023. Gerresheimer, ...
Gerresheimer AG
About the publication
08 November 2023 04:30PM
Groundbreaking ceremony for plant expansion in Querétaro, Mexico
DE000A0LD6E6
EQS-Media / 08.11.2023 / 16:30 CET/CEST Groundbreaking ceremony for plant expansion in Querétaro, Mexico Significant expansion of production capacities for RTF syringes for the North American market Investment volume of around 100 million Euros Düsseldorf, Germany, November 8, 2023. Gerresheimer, an innovative system an...
Gerresheimer AG
About the publication
18 October 2023 11:05AM
Gerresheimer awarded EcoVadis Gold status again
DE000A0LD6E6
Gerresheimer awarded EcoVadis Gold status again Gerresheimer among the top 5% of assessed businesses Total score increases to 72/100 points Status demonstrates consistent implementation of CSR strategy Duesseldorf, October 18, 2023 Gerresheimer, an innovative provider of systems and solutions and a global partner for the pharma, biotech, and cos...
Gerresheimer AG
About the publication
05 October 2023 07:00AM
Gerresheimer on track to another strong financial year
DE000A0LD6E6
Gerresheimer on track to another strong financial year Organic revenue growth of 12.6% in the first nine months of the financial year 2023 Adjusted EBITDA up organically by 20.6% Order intake at record high: new orders for syringes and pens for GLP-1 drugs Guidance for full-year 2023 confirmed Duesseldorf, October 5, 2023. Gerresheimer, innovat...
Gerresheimer AG
About the publication
06 July 2023 07:00AM
Gerresheimer continues dynamic growth in first half of 2023
DE000A0LD6E6
Gerresheimer continues dynamic growth in first half of 2023 Organic revenue growth of 16.6% in first half of 2023 Adjusted EBITDA up 23.0% organically Production capacities expanded in Europe, the United States, and Mexico Guidance for full year 2023 confirmed Duesseldorf, July 6, 2023. Gerresheimer, an innovative provider of systems and soluti...
Gerresheimer AG
About the publication
06 July 2023 07:00AM
Gerresheimer AG: Gerresheimer continues dynamic growth in first half of 2023
DE000A0LD6E6
Gerresheimer continues dynamic growth in first half of 2023 Organic revenue growth of 16.6% in first half of 2023 Adjusted EBITDA up 23.0% organically Production capacities expanded in Europe, the United States, and Mexico Guidance for full year 2023 confirmed Duesseldorf, July 6, 2023. Gerresheimer, an innovative provider of systems and soluti...
Gerresheimer AG
About the publication
07 June 2023 04:08PM
Annual General Meeting backs growth course
DE000A0LD6E6
Gerresheimer AG: Annual General Meeting backs growth course Dividend of EUR 1.25 per share after strong financial year 2022 High approval rates for all agenda items Forecast reaffirmed: double-digit growth in revenues and earnings Duesseldorf, June 7, 2023. The Annual General Meeting of Gerresheimer AG has expressed its confidence in the Manage...
Gerresheimer AG
About the publication
07 June 2023 04:08PM
Gerresheimer AG: Annual General Meeting backs growth course
DE000A0LD6E6
Gerresheimer AG: Annual General Meeting backs growth course Dividend of EUR 1.25 per share after strong financial year 2022 High approval rates for all agenda items Forecast reaffirmed: double-digit growth in revenues and earnings Duesseldorf, June 7, 2023. The Annual General Meeting of Gerresheimer AG has expressed its confidence in the Manage...
Gerresheimer AG
About the publication
18 April 2023 09:56PM
Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
DE000A0LD6E6
Gerresheimer AG successfully completes EUR 271.6 million capital increase 3.14 million new shares placed at EUR 86.50 with gross proceeds of EUR 271.6 million Strong investor demand underlines support for formula G strategy for profitable growth Proceeds from capital increase “opens up the opportunity to reach the next level of sustainable value...
Gerresheimer AG
About the publication
18 April 2023 09:56PM
Gerresheimer AG successfully completes EUR 271.6 million capital increase
DE000A0LD6E6
Gerresheimer AG successfully completes EUR 271.6 million capital increase 3.14 million new shares placed at EUR 86.50 with gross proceeds of EUR 271.6 million Strong investor demand underlines support for formula G strategy for profitable growth Proceeds from capital increase “opens up the opportunity to reach the next level of sustainable value...
Gerresheimer AG
About the publication
18 April 2023 09:53PM
Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
DE000A0LD6E6
Gerresheimer AG issues 3.140.000 million new shares at a placement price of EUR 86,50 per new share   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR OTHER COUNTRIES WHERE SUCH A PUBLICATION COULD BE UNLAWFUL   Duesseldorf, April 18, 2023 – Gerresheimer AG...
Gerresheimer AG
About the publication
18 April 2023 09:53PM
Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
DE000A0LD6E6
Gerresheimer AG issues 3.140.000 million new shares at a placement price of EUR 86,50 per new share   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR OTHER COUNTRIES WHERE SUCH A PUBLICATION COULD BE UNLAWFUL   Duesseldorf, April 18, 2023 – Gerresheimer AG...
Gerresheimer AG
About the publication
18 April 2023 05:54PM
Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
DE000A0LD6E6
Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR OTHER COUNTRIES WHERE SUCH A PUBLICATION COULD BE UNLA...
Gerresheimer AG
About the publication
18 April 2023 05:54PM
Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
DE000A0LD6E6
Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR OTHER COUNTRIES WHERE SUCH A PUBLICATION COULD BE UNLA...
Gerresheimer AG
About the publication
18 April 2023 05:49PM
Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
DE000A0LD6E6
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR OTHER COUNTRIES WHERE SUCH A PUBLICATION COULD BE UNLAWFUL Duesseldorf, April 18, 2023 – Today, the management board of Gerresheimer AG (ISIN DE000A0LD6E6), with the approval of the supervisory board, resolved t...
Gerresheimer AG
About the publication
18 April 2023 05:49PM
Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
DE000A0LD6E6
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR OTHER COUNTRIES WHERE SUCH A PUBLICATION COULD BE UNLAWFUL Duesseldorf, April 18, 2023 – Today, the management board of Gerresheimer AG (ISIN DE000A0LD6E6), with the approval of the supervisory board, resolved t...
Gerresheimer AG
About the publication
06 April 2023 07:00AM
Gerresheimer AG: Gerresheimer with a good start to 2023 financial year: Again double-digit growth in revenues and Adjusted EBITDA
DE000A0LD6E6
Gerresheimer with a good start to 2023 financial year: Again double-digit growth in revenues and Adjusted EBITDA First-quarter revenues grew organically by 21.0% Adjusted EBITDA up organically by 24.8% Gerresheimer confirms guidance for financial year 2023 Düsseldorf, Germany, April 6, 2023 - Gerresheimer AG, a leading provider of healthcare &am...
Gerresheimer AG
About the publication
06 April 2023 07:00AM
Again double-digit growth in revenues and Adjusted EBITDA
DE000A0LD6E6
Gerresheimer with a good start to 2023 financial year: Again double-digit growth in revenues and Adjusted EBITDA First-quarter revenues grew organically by 21.0% Adjusted EBITDA up organically by 24.8% Gerresheimer confirms guidance for financial year 2023 Düsseldorf, Germany, April 6, 2023 - Gerresheimer AG, a leading provider of healthcare &am...
Gerresheimer AG
About the publication
23 February 2023 07:00AM
Profitable growth company boosting revenue and adjusted EBITDA growth to double-digit levels
DE000A0LD6E6
Gerresheimer 2022: Profitable growth company boosting revenue and adjusted EBITDA growth to double-digit levels Consistent execution of strategy and strong fourth quarter performance has resulted in organic revenue growth of 16.2% for FY 2022 Organic growth in adjusted EBITDA of 10.2% for FY 2022, ahead of guidance Q4 2022 delivered double-digit...
Gerresheimer AG
About the publication
23 February 2023 07:00AM
Gerresheimer AG: Gerresheimer 2022: Profitable growth company boosting revenue and adjusted EBITDA growth to double-digit levels
DE000A0LD6E6
Gerresheimer 2022: Profitable growth company boosting revenue and adjusted EBITDA growth to double-digit levels Consistent execution of strategy and strong fourth quarter performance has resulted in organic revenue growth of 16.2% for FY 2022 Organic growth in adjusted EBITDA of 10.2% for FY 2022, ahead of guidance Q4 2022 delivered double-digit...
Gerresheimer AG
About the publication
06 December 2022 02:00PM
Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
DE000A0LD6E6
Capital Markets Day 2022 Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth Strong order intake in all areas with increasing revenue share of biological solutions and injectables New platform wins reinforce position as strategic partner of choice for the global pharma and biotec...
Gerresheimer AG
About the publication
06 December 2022 02:00PM
Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
DE000A0LD6E6
Capital Markets Day 2022 Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth Strong order intake in all areas with increasing revenue share of biological solutions and injectables New platform wins reinforce position as strategic partner of choice for the global pharma and biotec...
Gerresheimer AG
About the publication
12 October 2022 07:00AM
Gerresheimer reports double digit growth in revenue and earnings for the third quarter
DE000A0LD6E6
Gerresheimer reports double digit growth in revenue and earnings for the third quarter Organic revenue growth of 17.4% in the third quarter supported by continued strong demand for High Value Solutions Organic adjusted EBITDA up 13.3% Gerresheimer firmly on track to deliver on FY 2022 guidance Duesseldorf, October 12, 2022 – Gerresheimer AG, a l...
Gerresheimer AG
About the publication
12 October 2022 07:00AM
Gerresheimer AG: Gerresheimer reports double digit growth in revenue and earnings for the third quarter
DE000A0LD6E6
Gerresheimer reports double digit growth in revenue and earnings for the third quarter Organic revenue growth of 17.4% in the third quarter supported by continued strong demand for High Value Solutions Organic adjusted EBITDA up 13.3% Gerresheimer firmly on track to deliver on FY 2022 guidance Duesseldorf, October 12, 2022 – Gerresheimer AG, a l...
Gerresheimer AG
About the publication
07 September 2022 08:00AM
Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry
DE000A0LD6E6
Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry Two leading companies joined forces to develop a new Ready-To-Use solution platform based on EZ-fill® pre-sterilized platform Seamless integration into standard fill & finish lines Signific...
Gerresheimer AG
About the publication
07 September 2022 08:00AM
Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry
DE000A0LD6E6
Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry Two leading companies joined forces to develop a new Ready-To-Use solution platform based on EZ-fill® pre-sterilized platform Seamless integration into standard fill & finish lines Signific...
Gerresheimer AG
About the publication
17 August 2022 08:00AM
Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source
DE000A0LD6E6
Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source Pharma customers gain access to both companies’ integrated design, development and manufacturing expertise Gerresheimer serves as central point of contact Gerresheimer and Zollner tap into growing demand for digital and ...
Gerresheimer AG
About the publication
17 August 2022 08:00AM
Gerresheimer AG: Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source
DE000A0LD6E6
Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source Pharma customers gain access to both companies’ integrated design, development and manufacturing expertise Gerresheimer serves as central point of contact Gerresheimer and Zollner tap into growing demand for digital and ...
Gerresheimer AG
About the publication
09 August 2022 07:00AM
Gerresheimer invests up to 94 million Dollar in US production facility
DE000A0LD6E6
DGAP-Media / 09.08.2022 / 07:00 CET/CEST  Gerresheimer invests up to 94 million Dollar in US production facility Major expansion in the North American market Supported by U.S. Biomedical Advanced Research and Development Authority (BARDA) via 70/30 cost-share cooperative agreement New state-of-the-art forming lines in North Carolina incre...
Gerresheimer AG
About the publication
More Gerresheimer AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 6 14th November 2024 Siemssen, Dietmar DD
Short Seller (DE) 37 11th December 2024 Squarepoint Ops LLC SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN